Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea

We investigated the outcome of idarubicin plus N(4)-behenoyl-1-β-D-arabinofuranosyl cytosine (BHAC)-based chemotherapy (BHAC group, n=149) compared to idarubicin plus cytarabine-based chemotherapy (cytarabine group, n=191) for childhood acute myeloid leukemia (AML). Between January 1996 and December...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dae Hyoung, Chung, Nak Gyun, Cho, Bin, Kim, Hack Ki, Kang, Hyoung Jin, Shin, Hee Young, Ahn, Hyo Seop, Yoo, Keon Hee, Sung, Ki Woong, Koo, Hong Hoe, Kook, Hoon, Hwang, Tai Ju, Im, Ho Joon, Seo, Jong Jin, Park, Hyeon Jin
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2800026/
https://www.ncbi.nlm.nih.gov/pubmed/20052341
http://dx.doi.org/10.3346/jkms.2010.25.1.9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2800026/
https://www.ncbi.nlm.nih.gov/pubmed/20052341
http://dx.doi.org/10.3346/jkms.2010.25.1.9

Ejemplares similares